SEC Files Action Against Company and its CEO for Trading and Compensation-Related Violations

SEC Litigation Release

The SEC filed an injunctive action against CytoCore, Inc., the former chairman of its board ("Chairman"), and the company's CEO and CFO, alleging that they engaged in violative conduct relating to trading in the company stock and as to the Chairman's compensation. Among other things, the SEC complaint alleges that the Chairman acted as an unregistered broker by receiving transaction-based compensation for soliciting investors in the company.

Document Number

SEC LR-21811

Date

January 13, 2011

Cross References (links may require a Cabinet subscription)

SEC Complaint

Exchange Act §§ 10(b), 14(a), 15(a), 16(a)

Exchange Act Rules 10b-5, 14a-9, 16a-3